These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 22241899)

  • 1. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
    Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
    Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
    Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
    Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer.
    Williams JL; Kadera BE; Nguyen AH; Muthusamy VR; Wainberg ZA; Hines OJ; Reber HA; Donahue TR
    J Gastrointest Surg; 2016 Jul; 20(7):1331-42. PubMed ID: 27114246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T; Zhang MG; Yu XJ; Liu L
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA19-9 for detecting recurrence of pancreatic cancer.
    Azizian A; Rühlmann F; Krause T; Bernhardt M; Jo P; König A; Kleiß M; Leha A; Ghadimi M; Gaedcke J
    Sci Rep; 2020 Jan; 10(1):1332. PubMed ID: 31992753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
    Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
    Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
    J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
    Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
    Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
    World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance.
    Jia F; Liu M; Li X; Zhang F; Yue S; Liu J
    World J Surg Oncol; 2019 Sep; 17(1):163. PubMed ID: 31526392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
    Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.